[Federal Register Volume 59, Number 131 (Monday, July 11, 1994)]
[Unknown Section]
[Page 0]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 94-16696]


[[Page Unknown]]

[Federal Register: July 11, 1994]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

 

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health.

ACTION: Notice.

-----------------------------------------------------------------------

    The inventions listed below are owned by agencies of the U.S. 
Government and are available for licensing in the U.S. in accordance 
with 35 U.S.C. 207 to achieve expeditious commercialization of results 
of federally funded research and development. Foreign patent 
applications are filed on selected inventions to extend market coverage 
for U.S. companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent 
applications listed below may be obtained by writing to Steven M. 
Ferguson, Technology Licensing Specialist, Office of Technology 
Transfer, National Institutes of Health, 6011 Executive Boulevard, 
suite 325, Rockville, Maryland 20852-3804 (telephone 301/496-7735 ext. 
266; fax 301/402-0220). A signed Confidential Disclosure Agreement will 
be required to receive copies of the patent applications. Issued 
patents may be obtained from the Commissioner of Patents, U.S. Patent 
and Trademark Office, Washington, DC 20231.

Anti-Retroviral Compounds

Tam, S., Weigle, M., Broder, S., Mitsuya, H. (NCI)
Serial No. 07/064,631
Patent Reissued 14 Apr 92
U.S. Patent No. Re 33,887

    Dimeric dideoxynucleosides formed from two different 2',3'- 
dideoxynucleosides joined by a linking group are useful for treatment 
of HIV-infection and other retroviral infections. The linked 
dideoxynucleosides specifically inhibit HIV replication in vitro with 
less toxicity in human cells. Methods for the synthesis of these 
compounds are provided.

Method of Inhibiting Viral Replication Using IL-10

Yarchoan, R., Saville, W., Tosato, G., Taga, K. (NCI)
Filed 24 May 93
Serial No. 08/066,785

    The use of recombinant human interleukin 10 (rhIL-10) has been 
discovered to be a new potential means of treating HIV infection. In 
vitro studies with rhIL-10 have shown it to be an inhibitor of HIV 
infection in human monocytes and macrophages as well as having activity 
against HIV in certain T-cell and monocyte cell lines. This activity 
against HIV occurs both at the time of infection and when added to 
previously infected cell cultures.
    These effects occur at IL-10 concentrations that are lower than 
those which inhibit other immune functions. In addition, the use of IL-
10 to interfere with HIV replication is expected to result in the 
amelioration of Kaposi's sarcoma.

Novel Nonpeptidic Retroviral Protease Inhibitors

Randad, R., Pan, W., Burt, S., Erickson, J. (NCI)
Filed 8 Aug 93
Serial No. 08/106,686

    Novel nonpeptidic compounds designed to be inhibitors of the HIV 
protease enzyme have been discovered. These compounds thus have 
potential as possible pharmaceutical compositions for the inhibition 
HIV replication and the treatment of AIDS. Based upon SS isomers of 
substituted dibenzyl-5-hydroxyl-2-primidones, these compounds are 
expected to not have the problems associated with current peptide-based 
protease inhibitors such as poor oral absorption, poor stability, and 
rapid metabolism and elimination.

Use of Peptomers Derived From HIV-1 and HIV-2 as Vaccine Candidates

Robey, F., Harris-Kelson, T., Robert-Guroff, M. (NIDR)
Filed 19 Jan 94
Serial No. 08/184,330

    Novel conformationally constrained peptide polymer HIV vaccine 
candidates have been uncovered that generate a strong humoral immune 
response not seen against monomeric peptides. Termed ``peptomers'', 
these candidates are composed of specifically cross-linked synthetic 
peptide sequences from the highly conserved CD4 binding domains of the 
gp120 regions of HIV-1 and HIV-2. Although peptides from these regions 
of gp120 do not possess any conformation in solution, the polymerized 
forms were found to have conformations that resemble the theoretical 
conformations that might be found in these regions of the native gp120 
from HIV-1 and HIV-2. Certain peptomers from HIV-1 and HIV-2 bind CD4, 
the cell receptor for HIV-1 and HIV-2, and induce antibody responses in 
rabbits and rhesus monkeys that block in vitro HIV-1 infection.

    Dated: June 25, 1994.
 Barbara M. McGarey,
 Deputy Director, Office of Technology Transfer.
[FR Doc. 94-16696 Filed 7-8-94; 8:45 am]
BILLING CODE 4140-01-P